New hope for Tough-to-Treat uterine cancer
Disease control
Ongoing
This study is testing whether combining two drugs, niraparib and dostarlimab, can help control a specific, aggressive type of uterine cancer that has returned or persisted after standard chemotherapy. The goal is to see if this combination can shrink tumors and delay cancer growt…
Phase: PHASE2 • Sponsor: Casey Cosgrove • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC